New combo aims to keep lung cancer from returning in the chest
NCT ID NCT06771518
First seen Jun 07, 2026 · Last updated Jun 19, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether adding chest radiotherapy to maintenance immunotherapy (atezolizumab) can better control extensive-stage small cell lung cancer. About 37 adults whose cancer shrank after initial chemo-immunotherapy will receive targeted radiation to the chest along with atezolizumab. The goal is to see if this combination reduces local tumor recurrence at one year compared to historical rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
"Regina Elena" National Cancer Institute
RECRUITINGRome, Rome, 00144, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab
What this could lead to
If successful, this combination could reduce the chance of lung cancer returning in the chest after initial treatment, offering better local disease control.
What could go wrong
This is a small, early-phase trial with only 37 participants, so results may not apply broadly. The added radiotherapy may cause side effects like lung inflammation or fatigue.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.